Therapeutics: CD40; Fcγ receptor IIb (FCγR2B; CD32B); FCγR2A (CD32A)

In vitro and mouse studies suggest a CD40-targeting mAb with greater affinity for FCγR2B than for FCγR2A could help treat cancer. In in vitro binding assays, a variant of the CD40-agonizing mAb CP-870...